NanoString Technologies Inc. (NSDQ:NSTG) has announced a spatial molecular imaging platform for multiplexed analysis of RNA and protein expression for individual cells within intact tissue samples.
The spatial molecular imaging (SMI) platform supports tissue samples of Formalin-fixed paraffin-embedded and fresh-frozen specimens as well as organoids.
The SMI platform is designed to complement the company’s GeoMx digital spatial profiler, which supports the analysis of hundreds to thousands of RNAs or proteins from single cells within morphologically intact tissue samples. The profiler supports cellular and sub-cellular resolution.
“Spatial imagers measuring RNA and protein in situ at single-cell and sub-cell resolution are expected to emerge as an important product category over the next several years,” said Brad Gray, NanoString president and CEO, in prepared remarks.
The SMI will be formally available in the first half of 2021.
NanoString’s GeoMx has been a moneymaker for the company, helping to accelerate revenue growth in 2020. According to a briefing note from the investment bank UBS, the 3D spatial tool addresses one of the most attractive end-market opportunities in diagnostic tools.
Filed Under: Drug Discovery and Development
